title: The cardiopulmonary, eicosanoid, and tissue microanatomic effects of fluconazole during graded bacteremia.
abstract: Imidazole compounds have been shown to be beneficial in systemic sepsis and inflammation. The purpose of this study was to delineate the effects of fluconazole on systemic hemodynamics and on microanatomy of the heart, lung, liver, and kidney parenchyma of swine during graded bacteremia. Eighteen adult swine were studied in three groups: 1), anesthesia control; 2), septic control (Aeromonas hydrophila, 10(9)/mL, infused i.v. for 4 h); 3) fluconazole (fluconazole, 30 mg/kg i.v., followed by A. hydrophila infusion). After 4 h of graded bacteremia, autopsy was performed. Compared with the septic control group, cardiac index, oxygen delivery, and oxygen consumption were reduced significantly after fluconazole pretreatment, and mixed venous hemoglobin oxygen saturation (SVO2) and oxygen extraction were increased. Plasma thromboxane A2 and leukotriene levels were not affected by fluconazole. Computerized digital image analysis of the liver, heart, and kidney specimens revealed no statistically significant differences between the septic control group and fluconazole-pretreated animals. In the lung specimens, preinfusion of fluconazole decreased alveolar wall thickness in septic swine (anesthesia control group: 8.15 x 10(-3) +/- 1.3 x 10(-3)mm versus septic control group: 9.9 x 10(-3) +/- 1.3 x 10(-4) versus fluconazole group: 6.8 x 10(-3) +/- 1.6 x 10(-3); p < or = .05). Fluconazole pretreatment before graded bacteremia has no beneficial effect on cardiopulmonary performance or septic tissue edema of the heart, kidney, or liver. Tissue oxygen metabolism might be down-regulated by fluconazole. However, preinfusion of fluconazole appears to normalize the sepsis-induced increase in pulmonary alveolar wall thickness. The net significance of these changes on clinical outcome is not clear from these data.
authors.affiliation: Department of Surgery, Cooper Hospital/University Medical Center, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Camden 08103, USA.
authors.forename: K
authors.initials: K
authors.lastname: Salartash
authors.forename: J
authors.initials: J
authors.lastname: Gallucci
authors.forename: J
authors.initials: J
authors.lastname: Quinn
authors.forename: E
authors.initials: E
authors.lastname: Catalano
authors.forename: G
authors.initials: G
authors.lastname: Slotman
mesh_terms: D000758:Anesthesia; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology; D016470:Bacteremia / Q000188:drug therapy* / Q000209:etiology; D002467:Cell Nucleus / Q000473:pathology / Q000648:ultrastructure; D015777:Eicosanoids / Q000097:blood*; D005260:Female; D015725:Fluconazole / Q000494:pharmacology*; D006321:Heart / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D007091:Image Processing, Computer-Assisted; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008168:Lung / Q000187:drug effects / Q000473:pathology; D009206:Myocardium / Q000473:pathology; D010101:Oxygen Consumption; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000648:ultrastructure; D013552:Swine
chemical_list: D000893:Anti-Inflammatory Agents; D000935:Antifungal Agents; D015777:Eicosanoids; D015725:Fluconazole